NSCLCFourth-generation lung cancer therapyAnti-NSCLC agentBackground The epidermal growth factor receptor (EGFR) inhibitors represent the first-line therapy regimen for non-small cell lung cancer (NSCLC). Most of these inhibitors target the ATP-site to stop the aggressive development of NSCLC. ...
表皮生长因子受体(EGFR)突变是亚洲人群NSCLC中常见的驱动基因突变,携带EGFR突变的非小细胞肺癌(NSCLC)患者,靶向治疗药物如EGFR酪氨酸激酶抑制剂(TKIs)为一线治疗的标准选择,但这类患者通常对EGFR-TKIs初期反应良好,在治疗后10至14个月内会因...
Apatinib (YN968D1) is the first small-molecule-targeting drug with anti-tumor activity created in China for the treatment of advanced gastric cancer (GC) and hepatocellular carcinoma (HCC). It showed significant variation in the efficacy for treating can
High-throughput screening of the natural STK11 agonist dauricine: A biphenylisoquinoline alkaloid exerting anti-NSCLC effects and reversing gefitinib resistance Background Serine/threonine kinase 11 (STK11) deletion and downregulation caused cancer progression, and were widely associated with drug resistance...
2022年2月,JCI Insight发表文章“Anti–PD-L1 and anti-CD73 combination therapy promotes T cell response to EGFR-mutated NSCLC”。PD-L1抗体和CD73抗体联用能够有效治疗EGFR突变NSCLC,而单独用药在EGFR突变 NSCLC很难凑效。 在EGFR突变的NSCLC中EGFR信号通路促进CD73的表达。
Patients with chemotherapy-naïve, locally advanced or metastatic non—small cell lung cancer (NSCLC) who were treated in the phase 2 CITYSCAPE trial with tiragolumab, an inhibitor of the immunomodulatory receptor TIGIT, plus and anti–PD-L1 agent demonstrated better efficacy versus single-agent ...
Metastatic clear cell renal cell carcinoma (CCC) remains incurable despite advances in the development of anti-angiogenic targeted therapies and the emerge... I Hamaidi,C Coquard,S Danilin,... - 《Oncogene》 被引量: 0发表: 2019年 Adrenomedullin mediates pro-angiogenic and pro-inflammatory cytoki...
reducing cell cycle phase-dependent activity of chemotherapy, especially in the EGFR wild-type population. Considering that in western countries, this part represents most of all the patients who receive any treatment for A-NSCLC, we can understand how the combination of these two different kind of...
Motesanib was combined with panitumumab, a fully human anti-EGFR mAb, cisplatin and gemcitabine in a Phase I trial including 36 patients with advanced solid tumors (19 NSCLC). Among the 29 patients evaluable, one CR, 31% PR (six NSCLC patients) and 59% SD were observed. The most common ...
anti-cancer immunity. Moreover, the combination of elevated KEAP1 expression with anti-PD-L1 immunotherapy resulted in a synergistic effect on both tumor growth and cytotoxic T-cell activation. Additionally, we found that the expressions of KEAP1 and PD-L1 were associated with NSCLC prognosis. ...